Gilead Sciences, Inc. (GIS.F)
| Clôture précédente | 76,73 |
| Ouverture | 76,81 |
| Offre | 74,27 x 50000 |
| Vente | 74,34 x 50000 |
| Var. jour | 74,03 - 76,31 |
| Sur 52 semaines | 52,23 - 84,73 |
| Volume | |
| Volume moyen | 1 302 |
| Cap. boursière | 93,956B |
| Bêta (mensuel sur 5 ans) | 0,43 |
| Rapport P/E (sur 12 mois) | 30,60 |
| BPA (sur 12 mois) | 2,43 |
| Date de bénéfices | 02 févr. 2023 |
| Dividende et rendement à terme | 2,75 (3,61 %) |
| Date ex-dividende | 14 déc. 2022 |
| Objectif sur 1 an | S.O. |
- ACCESSWIRE
Gilead Sciences: A Career Rooted in Championing Diversity and Inclusion: Jesse's Story
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
- ACCESSWIRE
Gilead's Path to Equitable Global COVID-19 Treatment Access
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
- ACCESSWIRE
Gilead Sciences: Metastatic Breast Cancer Advocate Urges Black People to Join Clinical Trials
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.
